Invivo Therapeutics (NVIV) versus IRIDEX (IRIX) Head-To-Head Contrast

Invivo Therapeutics (NASDAQ: NVIV) and IRIDEX (NASDAQ:IRIX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Invivo Therapeutics and IRIDEX’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Invivo Therapeutics N/A -134.23% -109.16%
IRIDEX -42.22% -23.21% -19.03%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Invivo Therapeutics and IRIDEX, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invivo Therapeutics 0 1 0 0 2.00
IRIDEX 0 0 1 0 3.00

Invivo Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 736.82%. IRIDEX has a consensus price target of $13.00, indicating a potential upside of 60.69%. Given Invivo Therapeutics’ higher possible upside, equities research analysts plainly believe Invivo Therapeutics is more favorable than IRIDEX.

Valuation and Earnings

This table compares Invivo Therapeutics and IRIDEX’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Invivo Therapeutics N/A N/A -$23.43 million ($0.85) -0.84
IRIDEX $46.16 million 2.03 -$11.71 million ($1.70) -4.76

IRIDEX has higher revenue and earnings than Invivo Therapeutics. IRIDEX is trading at a lower price-to-earnings ratio than Invivo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

12.8% of Invivo Therapeutics shares are owned by institutional investors. Comparatively, 49.3% of IRIDEX shares are owned by institutional investors. 3.9% of Invivo Therapeutics shares are owned by insiders. Comparatively, 5.0% of IRIDEX shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Invivo Therapeutics has a beta of 3.22, meaning that its share price is 222% more volatile than the S&P 500. Comparatively, IRIDEX has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.

Summary

IRIDEX beats Invivo Therapeutics on 8 of the 13 factors compared between the two stocks.

Invivo Therapeutics Company Profile

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

IRIDEX Company Profile

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.

Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply